Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.50 |
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | PPARA | Q07869 | 6/20 | 0.48 |
| ▸ | PPARG | P37231 | 5/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486220 | 1.00 | CTSS (0.50) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL688341 | 1.00 | CTSS (0.50) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL30797870 | 0.93 | CTSS (0.49) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL6735984 | 0.93 | CTSS (0.46) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL30797986 | 0.93 | CTSS (0.49) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL20267196 | 0.88 | CTSS (0.47) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL20267198 | 0.88 | CTSS (0.47) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL1235161 | 0.87 | CTSK (0.49) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL12486933 | 0.87 | CTSK (0.49) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL343678 | 0.87 | CYP2D6 (0.55) | CTSSCTSKPPARAPPARGCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113501947-A | Polyester with amino group and preparation method thereof | 温州医科大学 | 2021-10-15 | — | — | CN | claimed |
| CN-105498838-B | A kind of Baeyer Villiger oxidation reaction catalysts and preparation method and application | 石家庄学院 | 2017-11-21 | — | — | CN | claimed |
| CN-105498838-A | Baeyer-Villiger oxidation reaction catalyst and preparation method and application thereof | UNIV SHIJIAZHUANG | 2016-04-20 | — | — | CN | claimed |
| CN-103724392-B | A kind of preparation method of amino acid phytosterol ester hydrochloride | JIANGNAN UNIVERSITY (CN) | 2016-03-02 | — | — | CN | claimed |
| CN-103724392-A | Preparation method of amino acid phytosterol ester hydrochloride | UNIV JIANGNAN | 2014-04-16 | — | — | CN | claimed |
| CN-102796169-B | Double saturated aliphatic chain alcohol Glu-Asp-Gly-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2014-01-29 | — | — | CN | claimed |
| CN-102796171-B | Double saturated aliphatic chain alcohol His-Gly-Glu-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2014-01-29 | — | — | CN | claimed |
| CN-102796170-B | Double saturated aliphatic chain alcohol His-Gly-Lys-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2014-01-29 | — | — | CN | claimed |
| CN-102796171-A | Double saturated aliphatic chain alcohol His-Gly-Glu-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-11-28 | — | — | CN | claimed |
| CN-102796170-A | Double saturated aliphatic chain alcohol His-Gly-Lys-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-11-28 | — | — | CN | claimed |
| CN-102796169-A | Double saturated aliphatic chain alcohol Glu-Asp-Gly-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-11-28 | — | — | CN | claimed |
| CN-100590068-C | Method for preparing primary amine carbon nano tube | UNIV TONGJI | 2010-02-17 | — | — | CN | claimed |
| CN-101177259-A | Method for preparing primary amine carbon nano tube | UNIV TONGJI (CN) | 2008-05-14 | — | — | CN | claimed |
| CN-1241935-C | Liquid phase sgnthesis method of thymus pentapeptide | UNIV LANZHOU (CN) | 2006-02-15 | — | — | CN | claimed |
| CN-1202131-C | Technology of one kettle method for liquid phase synthesizing thymopentapeptide | UNIV JILIN (CN) | 2005-05-18 | — | — | CN | claimed |
| CN-1513872-A | Liquid phase sgnthesis method of thymus pentapeptide | 兰州大学 | 2004-07-21 | — | — | CN | claimed |
| CN-1442428-A | Technology of one kettle method for liquid phase synthesizing thymopentapeptide | UNIV JILIN (CN) | 2003-09-17 | — | — | CN | claimed |
| US-6398857-B1 | ACCUSTIC PIEZOELECTRIC; HOT MELT INK JET PRINTING; BENZOIC ACID VEHICLE; ALKYL OR PHENYL CARBOXYLIC ACID VISCOSITY MODIFIER; RETAINS DESIRED HARDNESS | XEROX CORPORATION | 2002-06-04 | — | — | US | claimed |
| US-6395077-B1 | INKS WITH BENZOYLBENZOIC ACID AND COLORS | XEROX CORPORATION | 2002-05-28 | — | — | US | claimed |
| EP-4714961-A2 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4209483-B1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250115634-A1 | LIGAND, METHOD FOR PREPARING SAME, AND USE THEREOF | LNCTAC CO., LTD. (CN) | 2025-04-10 | — | — | US | disclosed |
| CN-119684406-A | Enzyme response self-assembled polypeptide prodrug loaded with camptothecine, preparation and application thereof | 东南大学 | 2025-03-25 | — | — | CN | disclosed |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | SHENZHEN JINGTAI TECHNOLOGY CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| CN-118234705-A | Aspartic acid derivative and application thereof in treatment of liver fibrosis, nonalcoholic hepatitis and other metabolic diseases | 深圳利沃生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| CN-118027017-A | BRM inhibitor | 苏州信诺维医药科技股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024056798-A1 | MACROCYCLIC CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-03-21 | — | — | WO | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-02-27 | — | — | US | disclosed |
| US-20240051985-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS INC (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| CN-117024476-A | diphenylphosphonooxy-X-phenol compound, preparation method and application in preparation of aspartame | 西北工业大学 | 2023-11-10 | — | — | CN | disclosed |
| CN-116640182-A | Transdermal delivery system for polypeptides and related compounds | 泰飞尔生物医药(苏州)有限公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2023143374-A1 | LIGAND, METHOD FOR PREPARING SAME, AND USE THEREOF | 成都凌泰氪生物技术有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-116283647-A | Prodrug modulators that integrate stress pathways | 卡里科生命科学有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116283977-A | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023083291-A1 | DERIVATIVE OF ASPARTIC ACID AND USE THEREOF IN TREATMENT OF METABOLIC DISEASES SUCH AS HEPATIC FIBROSIS AND NON-ALCOHOLIC HEPATITIS | 深圳利沃生物医药科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| CN-110573499-B | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230017637-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-01-19 | — | — | US | disclosed |
| US-20220396555-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-12-15 | — | — | US | disclosed |
| CN-113423685-B | Prodrug modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-115053184-A | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022127704-A1 | PROCESS FOR PREPARING CARBOXYL CYCLIC ACID ANHYDRIDE | 北京大学 | 2022-06-23 | — | — | WO | disclosed |
| EP-4011870-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RILUZOLE PRODRUGS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2022-06-15 | — | — | EP | disclosed |
| CN-109010830-B | Application of platelet related inhibitor in preparation of medicine for treating thrombocytopenia | 苏州大学 | 2022-06-07 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | THE UNIVERSITY OF TOLEDO (US) | 2021-11-30 | — | — | US | disclosed |
| US-11149043-B2 | Prodrug modulators of the integrated stress pathway | CALICO LIFE SCIENCES LLC (US) | 2021-10-19 | — | — | US | disclosed |
| CN-113501947-A | Polyester with amino group and preparation method thereof | 温州医科大学 | 2021-10-15 | — | — | CN | disclosed |
| CN-113501947-A | Polyester with amino group and preparation method thereof | 温州医科大学 | 2021-10-15 | — | — | CN | disclosed |
| CN-113423685-A | Prodrug modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-09-21 | — | — | CN | disclosed |
| US-11091423-B2 | Reagents and methods for esterification | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210236471-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-08-05 | — | — | US | disclosed |
| US-20210236470-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | 2021-08-05 | — | — | US | disclosed |
| US-20210230195-A1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2021-07-29 | — | — | US | disclosed |
| US-20210228549-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-07-29 | — | — | US | disclosed |
| US-11052070-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-07-06 | — | — | US | disclosed |
| CN-112341635-A | Emulsifier special for epoxy asphalt, epoxy emulsified asphalt and preparation method of epoxy emulsified asphalt | 浙江潮源新型建材股份有限公司 | 2021-02-09 | — | — | CN | disclosed |
| US-10905681-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2020-09-17 | — | — | US | disclosed |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200206362-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200190011-A1 | Reagents and Methods for Esterification | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2020-06-18 | — | — | US | disclosed |
| CN-111164071-A | Process for the preparation of intermediate compounds for the synthesis of medicaments | 株式会社LG化学 | 2020-05-15 | — | — | CN | disclosed |
| US-10639298-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (US) | 2020-05-05 | — | — | US | disclosed |
| WO-2020063824-A1 | NITROXOLINE PRODRUG AND USE THEREOF | 江苏亚虹医药科技有限公司 | 2020-04-02 | — | — | WO | disclosed |
| US-20200085794-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD. (JP) | 2020-03-19 | — | — | US | disclosed |
| US-10577303-B1 | Reagents and methods for esterification | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-03-03 | — | — | US | disclosed |
| US-10556018-B2 | Compositions and methods for delivery of agents | ARES CAPITAL CORPORATION, AS AGENT | 2020-02-11 | — | — | US | disclosed |
| CN-110526933-A | Biotin variants, streptavidin mutants and uses thereof | SAVID THERAPEUTICS INC | 2019-12-03 | — | — | CN | disclosed |
| CN-110433130-A | A kind of male's basic nursing liquid | SHANDONG CHUANYUN BIOTECHNOLOGY CO LTD | 2019-11-12 | — | — | CN | disclosed |
| CN-110312533-A | Prodrugs of cytotoxic active agents having an enzymatically cleavable group | 拜耳公司 | 2019-10-08 | — | — | CN | disclosed |
| CN-104945309-B | New nitroso compound and application thereof as nitroxyl donors | 卡尔迪奥克斯尔制药公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-109705325-A | A kind of chirality petchem and preparation method thereof | 浙江工业大学 | 2019-05-03 | — | — | CN | disclosed |
| CN-106163509-B | β -substituted β -amino acids and analogs as chemotherapeutic agents | 夸德里加生物科学公司 | 2019-05-03 | — | — | CN | disclosed |
| US-20190117798-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3458479-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10207010-B2 | Compositions and methods for delivery of agents | MODERNATX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-3386484-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| CN-108026026-A | Beta-amino acids and analog and its application as the β-substituted of chemotherapeutics | 夸德里加生物科学公司 | 2018-05-11 | — | — | CN | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| CN-103402516-B | Compound, composition and application method as antiviral drugs | 富津世生物技术有限公司 | 2018-01-30 | — | — | CN | disclosed |
| EP-3265448-A1 | RILUZOLE PRODRUGS AND THEIR USE | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2018-01-10 | — | — | EP | disclosed |
| CN-107567438-A | Riluzole prodrug and application thereof | 拜尔哈文制药股份有限公司 | 2018-01-09 | — | — | CN | disclosed |
| WO-2017214335-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| CN-105498838-B | A kind of Baeyer Villiger oxidation reaction catalysts and preparation method and application | 石家庄学院 | 2017-11-21 | — | — | CN | disclosed |
| US-9795678-B2 | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound | ADOCIA (FR) | 2017-10-24 | — | — | US | disclosed |
| WO-2017172476-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017099823-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| CN-106459089-A | Biotin variants, streptavidin mutants and uses thereof | 赛威德医疗公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Ashvattha Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-9526794-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526794-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2016-12-27 | — | — | US | disclosed |
| CN-106163509-A | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents | 夸德里加生物科学公司 | 2016-11-23 | — | — | CN | disclosed |
| CN-106132414-A | Aryl lactams inhibitors of kinases | 百时美施贵宝公司 | 2016-11-16 | — | — | CN | disclosed |
| WO-2016140879-A9 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016140878-A9 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-10-20 | — | — | WO | disclosed |
| CN-102453001-B | Thiomorpholine compounds and its production and use | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2016-06-01 | — | — | CN | disclosed |
| CN-104136997-B | Composition for forming highly adhesive resist underlayer film | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-11 | — | — | CN | disclosed |
| CN-105498838-A | Baeyer-Villiger oxidation reaction catalyst and preparation method and application thereof | UNIV SHIJIAZHUANG | 2016-04-20 | — | — | CN | disclosed |
| CN-105498838-A | Baeyer-Villiger oxidation reaction catalyst and preparation method and application thereof | UNIV SHIJIAZHUANG | 2016-04-20 | — | — | CN | disclosed |
| US-9195137-B2 | Composition for forming highly adhesive resist underlayer film | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-11-24 | — | — | US | disclosed |
| US-9195137-B2 | Composition for forming highly adhesive resist underlayer film | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-11-24 | — | — | US | disclosed |
| WO-2015125820-A1 | BIOTIN VARIANT, STREPTAVIDIN MUTANT, AND USES THEREOF | サヴィッド・セラピューティックス株式会社 | 2015-08-27 | — | — | WO | disclosed |
| US-20150031206-A1 | COMPOSITION FOR FORMING HIGHLY ADHESIVE RESIST UNDERLAYER FILM | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150031206-A1 | COMPOSITION FOR FORMING HIGHLY ADHESIVE RESIST UNDERLAYER FILM | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-01-29 | — | — | US | disclosed |
| CN-102548993-B | Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals | SANOFI AVENTIS | 2014-12-10 | — | — | CN | disclosed |
| WO-2014186465-A1 | ANTI-INFLUENZA COMPOSITIONS AND METHODS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | WO | disclosed |
| CN-104136997-A | Composition for forming highly adhesive resist underlayer film | NISSAN CHEMICAL IND LTD | 2014-11-05 | — | — | CN | disclosed |
| CN-103896923-A | Blood sugar reducing compound, preparation method of blood sugar reducing compound, medicine composition including blood sugar reducing compound and application of medicine composition | BEIJING LABSOLUTIONS PHARMACEUTICALS CO LTD | 2014-07-02 | — | — | CN | disclosed |
| US-8735582-B2 | Method for producing carboxylic anhydride and arylboronic acid compound | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-05-27 | — | — | US | disclosed |
| CN-102796169-B | Double saturated aliphatic chain alcohol Glu-Asp-Gly-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2014-01-29 | — | — | CN | disclosed |
| CN-102796171-B | Double saturated aliphatic chain alcohol His-Gly-Glu-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2014-01-29 | — | — | CN | disclosed |
| CN-102796170-B | Double saturated aliphatic chain alcohol His-Gly-Lys-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2014-01-29 | — | — | CN | disclosed |
| CN-103402516-A | Compounds useful as antiviral agents, compositions, and methods of use | FUZIANS BIOMEDICALS INC | 2013-11-20 | — | — | CN | disclosed |
| CN-103402975-A | Beta-hydroxyalkylamide and resin composition | TOYO INK SC HOLDINGS CO LTD | 2013-11-20 | — | — | CN | disclosed |
| EP-2459557-B1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (US) | 2013-05-30 | — | — | US | disclosed |
| US-8415336-B2 | Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-04-09 | — | — | US | disclosed |
| US-8343999-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| CN-102796171-A | Double saturated aliphatic chain alcohol His-Gly-Glu-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-11-28 | — | — | CN | disclosed |
| CN-102796170-A | Double saturated aliphatic chain alcohol His-Gly-Lys-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-11-28 | — | — | CN | disclosed |
| CN-102796169-A | Double saturated aliphatic chain alcohol Glu-Asp-Gly-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-11-28 | — | — | CN | disclosed |
| US-20120232081-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-09-13 | — | — | US | disclosed |
| CN-102595888-A | Single diastereomers of 4-fluoroglutamine and methods for their preparation and use | UNIV PENNSYLVANIA | 2012-07-18 | — | — | CN | disclosed |
| CN-102548993-A | Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals | SANOFI AVENTIS | 2012-07-04 | — | — | CN | disclosed |
| EP-2459557-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-06-06 | — | — | EP | disclosed |
| CN-102453001-A | Thiomorpholine compound and preparation method and application thereof | INST MATERIA MEDICA CAMS | 2012-05-16 | — | — | CN | disclosed |
| EP-1963319-B1 | HETEROARYLPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-04-11 | — | — | EP | disclosed |
| EP-1963319-B1 | HETEROARYLPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-04-11 | — | — | EP | disclosed |
| US-7842626-B2 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842626-B2 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-7781443-B2 | cholesteryl ester transfer protein (CETP) anatgonists such as 2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester, having improved bioavailability | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20100120770-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-13 | — | — | US | disclosed |
| CN-100590068-C | Method for preparing primary amine carbon nano tube | UNIV TONGJI | 2010-02-17 | — | — | CN | disclosed |
| EP-2132203-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-12-16 | — | — | EP | disclosed |
| US-7618982-B2 | Heteroarylpyrrolopyridinones active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-11-17 | — | — | US | disclosed |
| US-7618982-B2 | Heteroarylpyrrolopyridinones active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-11-17 | — | — | US | disclosed |
| US-7618982-B2 | Heteroarylpyrrolopyridinones active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-11-17 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-7473658-B2 | Partially fluorinated amino acid derivatives as gelling and surface active agents | E. I. DU PONT NEMOURS AND COMPANY (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473658-B2 | Partially fluorinated amino acid derivatives as gelling and surface active agents | E. I. DU PONT NEMOURS AND COMPANY (US) | 2009-01-06 | — | — | US | disclosed |
| WO-2008124757-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-1444202-B1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-20080113172-A1 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080113172-A1 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080113573-A1 | Partially fluorinated amino acid derivatives as gelling and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080113573-A1 | Partially fluorinated amino acid derivatives as gelling and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| CN-101177259-A | Method for preparing primary amine carbon nano tube | UNIV TONGJI (CN) | 2008-05-14 | — | — | CN | disclosed |
| US-RE39991-E1 | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation | DOW AGROSCIENCES LLC (US) | 2008-01-01 | — | — | US | disclosed |
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| US-7288623-B2 | Cyclic peptide tube | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| WO-2007071621-A1 | HETEROARYLPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| US-20070032485-A1 | Tetrahydronaphthyridine derivatives and a process for preparing the same | TANABE SEIYAKU CO., LTD. | 2007-02-08 | — | — | US | disclosed |
| CN-1906206-A | Di-steroidal prodrugs of estradiol | GALEN CHEMICALS LTD (US) | 2007-01-31 | — | — | CN | disclosed |
| CN-1906207-A | Di-steroidal prodrugs of ethinyl estradiol | GALEN CHEMICALS LTD (US) | 2007-01-31 | — | — | CN | disclosed |
| EP-1732924-A2 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1709061-A1 | DI-STEROIDAL PRODRUGS OF ETHINYL ESTRADIOL | Warner Chilcott Company Inc. (PR) | 2006-10-11 | — | — | EP | disclosed |
| EP-1709060-A1 | DI-STEROIDAL PRODRUGS OF ESTRADIOL | Warner Chilcott Company Inc. (PR) | 2006-10-11 | — | — | EP | disclosed |
| US-7067504-B2 | Di-steroidal prodrugs of ethinyl estradiol | WARNER CHILCOTT COMPANY, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-7067505-B2 | Di-steroidal prodrugs of estradiol | WARNER CHILCOTT COMPANY, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| WO-2006044230-A1 | WATER SOLUBLE PRODRUGS OF COX-2 INHIBITORS | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| CN-1241935-C | Liquid phase sgnthesis method of thymus pentapeptide | UNIV LANZHOU (CN) | 2006-02-15 | — | — | CN | disclosed |
| WO-2005095395-A2 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| WO-2005070950-A1 | DI-STEROIDAL PRODRUGS OF ETHINYL ESTRADIOL | WARNER CHILCOTT COMPANY, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070949-A1 | DI-STEROIDAL PRODRUGS OF ESTRADIOL | WARNER CHILCOTT COMPANY, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005069750-A2 | THERAPEUTIC COMPOSITION WITH NANOSCALE ACTIVATION AGENTS | HEMOLYTICS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050159399-A1 | Di-steroidal prodrugs of estradiol | GALEN (CHEMICALS) LIMITED (IE) | 2005-07-21 | — | — | US | disclosed |
| US-20050159609-A1 | Di-steroidal prodrugs of ethinyl estradiol | GALEN (CHEMICALS) LIMITED (IE) | 2005-07-21 | — | — | US | disclosed |
| CN-1202131-C | Technology of one kettle method for liquid phase synthesizing thymopentapeptide | UNIV JILIN (CN) | 2005-05-18 | — | — | CN | disclosed |
| EP-1487435-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| CN-1513872-A | Liquid phase sgnthesis method of thymus pentapeptide | 兰州大学 | 2004-07-21 | — | — | CN | disclosed |
| CN-1148346-C | Hydrazine derivative | - | 2004-05-05 | — | — | CN | disclosed |
| US-20040024176-A1 | Cyclic peptide tube | THE SCRIPPS RESEARCH INSTITUTE | 2004-02-05 | — | — | US | disclosed |
| WO-2003077907-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
| EP-0723554-B1 | CYCLIC PEPTIDE TUBE | SCRIPPS RESEARCH INST (US) | 2003-09-24 | — | — | EP | disclosed |
| CN-1442428-A | Technology of one kettle method for liquid phase synthesizing thymopentapeptide | UNIV JILIN (CN) | 2003-09-17 | — | — | CN | disclosed |
| US-6613875-B1 | Cyclic peptide tube | THE SCRIPPS RESEARCH INSTITUTE | 2003-09-02 | — | — | US | disclosed |
| US-20020173468-A1 | MODIFIED CYTOSTATIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-21 | — | — | US | disclosed |
| US-6398857-B1 | ACCUSTIC PIEZOELECTRIC; HOT MELT INK JET PRINTING; BENZOIC ACID VEHICLE; ALKYL OR PHENYL CARBOXYLIC ACID VISCOSITY MODIFIER; RETAINS DESIRED HARDNESS | XEROX CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-6395077-B1 | INKS WITH BENZOYLBENZOIC ACID AND COLORS | XEROX CORPORATION | 2002-05-28 | — | — | US | disclosed |
| CN-1309634-A | Hydrazine derivs. | HOFFMANN LA ROCHE (CH) | 2001-08-22 | — | — | CN | disclosed |
| CN-1233237-A | Heteroaryl succinamides and their use as metalloproteinase inhibitors | AGOURON PHARMA (US) | 1999-10-27 | — | — | CN | disclosed |
| US-5616788-A | FOR SOLID PHASE PEPTIDE SYNTHESIS | HYUNDAI PHARM. IND. CO., LTD. (KR) | 1997-04-01 | — | — | US | disclosed |
| EP-0723554-A1 | CYCLIC PEPTIDE TUBE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-07-31 | — | — | EP | disclosed |
| CN-1032212-C | N-protected alpha-L-aspartyl-L-methyl phenylalaninate | MITSUI TOATSU CHEMICALS (JP) | 1996-07-03 | — | — | CN | disclosed |
| WO-1995010535-A1 | CYCLIC PEPTIDE TUBE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-04-20 | — | — | WO | disclosed |
| CN-1081681-A | Amino sugar derivative | DAIICHI SEIYAKU CO (JP) | 1994-02-09 | — | — | CN | disclosed |
| US-5190782-A | Dietetics | NABISCO, INC. (US) | 1993-03-02 | — | — | US | disclosed |
| US-5021439-A | Senile dementia and memory dysfunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-04 | — | — | US | disclosed |
| US-5017567-A | Steroid antiinflammatory | SCHERING CORPORATION (US) | 1991-05-21 | — | — | US | disclosed |
| EP-0403600-A4 | DEPROTECTION OF PROTECTED PEPTIDES | — | 1991-03-13 | — | — | EP | disclosed |
| EP-0403600-A1 | DEPROTECTION OF PROTECTED PEPTIDES | THE ROCKEFELLER UNIVERSITY (US) | 1990-12-27 | — | — | EP | disclosed |
| EP-0367393-A2 | New heterocyclic compounds, production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1990-05-09 | — | — | EP | disclosed |
| WO-1990002138-A1 | DEPROTECTION OF PROTECTED PEPTIDES | THE ROCKEFELLER UNIVERSITY (US) | 1990-03-08 | — | — | WO | disclosed |
| US-4906635-A | Carboxyalkyl dipeptides as antiglaucoma agents | SCHERING CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
| CN-1036581-A | N-is protected the preparation method of 2-L-aspartyl-L-phenylalanine methyl esters | MITSUI TOATSU CHEMICALS (JP) | 1989-10-25 | — | — | CN | disclosed |
| US-4778795-A | Carboxyalkyl dipeptides as antiglaucoma agents | SCHERING CORPORATION (US) | 1988-10-18 | — | — | US | disclosed |
| US-4642315-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1987-02-10 | — | — | US | disclosed |
| CN-86101394-A | The preparation method of amino acid derivative and application thereof | — | 1986-12-03 | — | — | CN | disclosed |
| CN-86103254-A | A kind of method for preparing the addition compound of dipeptides and amine | — | 1986-11-26 | — | — | CN | disclosed |
| US-4616012-A | BENZOTHIADIZINYL AND QUINAZOLINYL DERIVATIVES | SCHERING CORPORATION (US) | 1986-10-07 | — | — | US | disclosed |
| US-4587234-A | HYPOTENSIVES | E. R. SQUIBB & SONS, INC. (US) | 1986-05-06 | — | — | US | disclosed |
| US-4499079-A | ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-02-12 | — | — | US | disclosed |
| US-4499079-A | ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (49 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113172-A1 | Partially fluorinated compositions and surface active agents | FLNB, FLNA, FSCN1 | CTSS 2311/4885CTSK 1579/4885PPARA 463/4885 |
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885PPARA 4317/4885 |
| US-20050159399-A1 | Di-steroidal prodrugs of estradiol | CYP19A1, HSD17B11, ESR1 | CTSS 1881/4885CTSK 2208/4885PPARA 643/4885 |
| US-10905681-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885PPARA 4317/4885 |
| US-11149043-B2 | Prodrug modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | CTSS 2876/4885CTSK 3395/4885PPARA 2773/4885 |
| US-20200190011-A1 | Reagents and Methods for Esterification | ADCY1, ADCY4, ADCY7 | CTSS 2857/4885CTSK 2795/4885PPARA 669/4885 |
| US-20040024176-A1 | Cyclic peptide tube | SGTA, VIP, TIMCC | CTSS 4457/4885CTSK 4263/4885PPARA 4307/4885 |
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885PPARA 4317/4885 |
| US-20240051985-A1 | METTL3 MODULATORS | METTL3, METTL16, METTL14 | CTSS 4285/4885CTSK 4088/4885PPARA 3704/4885 |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885PPARA 4317/4885 |
| US-20190117798-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | CTSS 2817/4885CTSK 3216/4885PPARA 3086/4885 |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | PAM, UACA, FLT1 | CTSS 4799/4885CTSK 4773/4885PPARA 575/4885 |
| US-11091423-B2 | Reagents and methods for esterification | ADCY1, ADCY4, ADCY7 | CTSS 2857/4885CTSK 2795/4885PPARA 669/4885 |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | CCR3, CCR1, CCR9 | CTSS 3822/4885CTSK 4155/4885PPARA 1580/4885 |
| US-20210230195-A1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | CTSS 2876/4885CTSK 3395/4885PPARA 2773/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885PPARA 4317/4885 |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | GOT1, ACAT1, GOT2 | CTSS 776/4885CTSK 927/4885PPARA 3673/4885 |
| US-10577303-B1 | Reagents and methods for esterification | ADCY1, ADCY4, ADCY7 | CTSS 2857/4885CTSK 2795/4885PPARA 669/4885 |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | CTSS 503/4885CTSK 543/4885PPARA 4402/4885 |
| US-20020173468-A1 | MODIFIED CYTOSTATIC AGENTS | TP53, PTMS, ANXA5 | CTSS 1070/4885CTSK 1403/4885PPARA 1615/4885 |
| US-10556018-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | CTSS 2817/4885CTSK 3216/4885PPARA 3086/4885 |
| US-20200206362-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | CTSS 2817/4885CTSK 3216/4885PPARA 3086/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885PPARA 4317/4885 |
| US-20210236471-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885PPARA 4317/4885 |
| US-10207010-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | CTSS 2817/4885CTSK 3216/4885PPARA 3086/4885 |
| US-20230017637-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885PPARA 4317/4885 |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | MAP3K1, MAP3K19, MAP3K3 | CTSS 2183/4885CTSK 1284/4885PPARA 3222/4885 |
| US-11052070-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885PPARA 4317/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | CTSS 2999/4885CTSK 2996/4885PPARA 2569/4885 |
| US-20250115634-A1 | LIGAND, METHOD FOR PREPARING SAME, AND USE THEREOF | SIGLEC7, ASGR1, ADGRF1 | CTSS 3075/4885CTSK 3975/4885PPARA 2752/4885 |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | APEH, CYP2C9, ALDH1A2 | CTSS 440/4885CTSK 416/4885PPARA 4295/4885 |
| US-20100120770-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | TTBK1, ERBB2, TEC | CTSS 3568/4885CTSK 1326/4885PPARA 2748/4885 |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | UACA, PAM, JAK3 | CTSS 4760/4885CTSK 4792/4885PPARA 486/4885 |
| US-20070032485-A1 | Tetrahydronaphthyridine derivatives and a process for preparing the same | CETP, MTTP, NPC1L1 | CTSS 2569/4885CTSK 2574/4885PPARA 3203/4885 |
| US-20050159609-A1 | Di-steroidal prodrugs of ethinyl estradiol | ESR1, HSD17B11, CYP19A1 | CTSS 1637/4885CTSK 1718/4885PPARA 726/4885 |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | CTSS 503/4885CTSK 543/4885PPARA 4402/4885 |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | GOT1, ACAT1, GOT2 | CTSS 776/4885CTSK 927/4885PPARA 3673/4885 |
| US-20200085794-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885PPARA 4317/4885 |
| US-10639298-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | CTSS 503/4885CTSK 543/4885PPARA 4402/4885 |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | CTSS 2817/4885CTSK 3216/4885PPARA 3086/4885 |
| US-20210236470-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | CTSS 503/4885CTSK 543/4885PPARA 4402/4885 |
| US-20120232081-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, ACE, PM20D2 | CTSS 462/4885CTSK 409/4885PPARA 3032/4885 |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | GOT1, GOT2, GLS2 | CTSS 958/4885CTSK 1138/4885PPARA 211/4885 |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | CTSS 2817/4885CTSK 3216/4885PPARA 3086/4885 |
| US-20210228549-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885PPARA 4317/4885 |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885PPARA 4317/4885 |
| US-20220396555-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | CTSS 503/4885CTSK 543/4885PPARA 4402/4885 |
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | CTSS 348/4885CTSK 748/4885PPARA 3639/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | CTSS 348/4885CTSK 748/4885PPARA 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.